CLINICAL_TRIALS
trial_result
· 2008-07-15
Clinical Trial Update: Phase II Study of CAP-232 in Patients With Refractory Metastatic Renal Cell Carcinoma [Phase 2]
Summary
Phase II trial of CAP-232 in refractory metastatic renal cell carcinoma has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Thallion Pharmaceuticals | Conditions: Carcinoma, Renal Cell | Phase 2 | Status: COMPLETED